Adebrelimab Combined With Neoadjuvant Chemoradiotherapy for Esophageal Squamous Cell Carcinoma

Abroad (travel likely)RecruitingPHASE2

Conditions

Esophageal Squamous Cell Carcinoma (ESCC)

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, Guangzhou, Guangdong, China
Contact: Study coordinator (Baisheng Chen Chen) · Pason06213367@163.com · +86-13560471611

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

KC1036 in Combination With PD-1 Antibody and Platinum-based Chemotherapy for First-line Advanced Esophageal Cancer

Esophageal Squamous Cell Carcinoma (ESCC)

Abroad (travel likely)RecruitingPHASE2

Beijing, China

Neoadjuvant Immunochemotherapy and Chemoradiotherapy Followed by Surgery for Advanced Esophageal Squamous Cell Carcinoma

ESCC · Total Neoadjuvant Treatment · Pathological Complete Response

Abroad (travel likely)RecruitingPHASE2

Taipei, Taiwan

Adebrelimab ±Induction Chemotherapy Followed by Concurrent Chemoradiotherapy for Unresectable Locally Advanced ESCC

Esophageal Squamous Cell Carcinoma · Immunotherapy · Biomarkers

Abroad (travel likely)RecruitingPHASE2

Fuzhou, China

A Study of Sigvotatug Vedotin in Advanced Solid Tumors

Carcinoma, Non-Small Cell Lung · Squamous Cell Carcinoma of Head and Neck · HER2 Negative Breast Neoplasms

Abroad (travel likely)RecruitingPHASE1

Anchorage, United States · Fayetteville, United States